|CRDAMC Homepage | CRDAMC Library Phone #: (254) 288-8366 | CRDAMC Library Fax #: (254) 288-8368|
Chemotherapy for Testicular Cancer
by Jondavid Pollock, MD, PhD
Chemotherapy uses drugs to kill testicular cancer cells. The drugs enter the bloodstream and travel through the body to the cancer cells. Chemotherapy is generally used after surgery, if testicular cancer has spread beyond the primary site, or to relieve symptoms of metastatic cancer. For nonseminomas, it may be used in combination with radiation therapy (called chemoradiation).
Chemotherapy Drugs and Delivery
There are a variety of chemotherapy drugs. A combination of drugs is generally more effective. The choice and combination of drugs will be based on your particular cancer and reaction to drugs. Chemotherapy drugs for testicular cancer may include:
Chemotherapy is most often given through an IV, but some forms can be given by mouth. It is delivered in cycles over a set period of time. A medical oncologist will determine how many cycles of chemotherapy are needed and what combination of drugs will work best.
Even with chemotherapy, testicular cancer can come back. If this is the case, a peripheral stem cell transplant may be an option.
A peripheral stem cell transplant uses healthy stem cells (immature, unformed cells) from the circulating blood in your body or a donor to restore normal blood cell function. The cells travel to bone marrow sites throughout the body and slowly repopulate numbers of red or white blood cells, or platelets. If the transplant is successful, the newly injected cells should be free of cancer and capable of producing healthy cells.
Healthy stem cells are harvested from the patient's own body. They are extracted from circulating blood. Circulating blood removed from the body is spun in a machine to separate the components in a process called apheresis. The blood is then circulated back into the body. The stem cells are frozen until all malignant testicular cancer cells are eliminated by high-dose chemotherapy. Lastly, the healthy stem cells are returned to the body to repopulate the blood cell count.
Side Effects and Management TOP
Though the drugs are targeted to cancer cells, they can affect healthy cells as well. The death of cancer cells and impact on healthy cells can cause a range of side effects. A medical oncologist will work to find the best drug combination and dosage to have the most impact on the cancer cells and minimal side effects on healthy tissue. Side effects or complications from chemotherapy may include:
A variety of treatments are available to help manage side effects including medication, lifestyle changes, and alternative treatments. In some cases, the chemotherapy regimen may be adjusted to reduce severe side effects. The earlier the side effects are addressed, the more likely they will be controlled with a minimum of discomfort.
Chemotherapy for testicular cancer. American Cancer Society website. Available at: https://www.cancer.org/cancer/testicular-cancer/treating/chemotherapy.html. Updated February 12, 2016. Accessed September 21, 2017.
Drugs approved for testicular cancer. National Cancer Institute website. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/testicular. Updated August 18, 2016. Accessed September 21, 2017.
High-dose chemotherapy and stem cell tranplant for testicular cancer. American Cancer Society website. Available at: https://www.cancer.org/cancer/testicular-cancer/treating/high-dose-chemo-stem-cell.html. Updated February 12, 2016. Accessed September 21, 2017.
Management of nonseminoma testicular cancer. EBSCO DynaMed Plus website. Available at: http://www.dynamed.... Updated May 31, 2017. Accessed September 21, 2017.
Management of seminoma. EBSCO DynaMed Plus website. Available at: http://www.dynamed.... Updated May 31, 2017. Accessed September 21, 2017.
8/11/2011 DynaMed Plus Systematic Literature Surveillance http://www.dynamed...: Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214. J Clin Oncol. 2011;29(8):957-962.
Last reviewed September 2017 by EBSCO Medical Review Board Mohei Abouzied, MD, FACP
Last Updated: 9/21/2017
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at email@example.com. Our Health Library Support team will respond to your email request within 2 business days.